Patents by Inventor David T. Winn
David T. Winn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8415295Abstract: Dipeptidyl peptidase IV (DPP-IV)-inhibiting compounds are provided that have formula I: wherein n is 1 to 3; X is CH2; S; O; CF2 or C(CH3)2; Z is H; halogen; hydroxyl; (C1-6)alkoxy; (C1-12)alkyl; (C3-12)cycloalkyl; phenyl; or heteroaryl; where the phenyl and heteroaryl groups are optionally mono- or independently plurisubstituted with R7; optionally, X together with an adjacent ring carbon and Z form a fused cyclopropyl; and optionally, one of the bonds in the ring containing X is a double bond; and CriRii, R1, R1, R3, R4 and R5 are as described herein. Methods for preparing these compounds, and methods for treating diabetes, especially Type II diabetes, and other related diseases are described using the compounds of formula I in pharmaceutical compositions which contain these compounds. Pharmaceutical compositions which contain combinations of these compounds with other antidiabetic agents are also described herein.Type: GrantFiled: January 22, 2010Date of Patent: April 9, 2013Assignee: Phenomix CorporationInventors: David Alan Campbell, David T. Winn, Juan Manuel Betancort
-
Patent number: 7906658Abstract: The present invention is directed to a method of treatment of a malcondition that can be regulated or normalized via inhibition of DPP-IV. The method involves administration of an effective amount of a pyrrolidine compound of the invention, such as would be present in a pharmaceutical composition of the invention, to mammals, especially humans, to affect a malcondition that can be regulated or normalized via inhibition of DPP-IV.Type: GrantFiled: August 2, 2007Date of Patent: March 15, 2011Assignee: Phenomix CorporationInventors: David Alan Campbell, David T. Winn, Juan Manuel Betancort
-
Patent number: 7884217Abstract: The present invention is directed to pyrrolidinylaminoacetyl pyrrolidine boronic acid compounds that display selective, potent dipeptidyl peptidase IV inhibitory activity. These compounds are useful for the treatment of disorders that can be regulated or normalized via inhibition of DPP-IV including those characterized by impaired glycemic control such as Diabetes Mellitus and related conditions. The compounds can be administered alone or with another medicament that displays pharmacological activity for treatment of these and other diseases.Type: GrantFiled: October 31, 2007Date of Patent: February 8, 2011Assignee: Phenomix CorporationInventors: David Alan Campbell, David T. Winn, Juan Manuel Betancort
-
Publication number: 20100323953Abstract: The present invention provides novel macrocyclic compounds that mimic peptide substrates of the hepatitis C viral protease and inhibit the viral protease, more particularly as inhibitors of the NS3 serine protease from hepatitis C virus. Methods for synthesis of the compounds are also provided. The compounds find utility as antiviral agents directed at hepatitis C. The invention further provides methods of employing such inhibitors, alone or in combination with other therapeutic agents, to treat hepatitis C infection in a subject in need of such treatment.Type: ApplicationFiled: January 4, 2008Publication date: December 23, 2010Applicant: Phenomix CorporationInventors: David Alan Campbell, Michael E. Hepperle, David T. Winn, Juan Manuel Betancort
-
Patent number: 7825139Abstract: Compounds that selectively inhibit dipeptidyl peptidase-IV over closely related dipeptidyl peptidases are those of Formula (I): as well as pharmaceutically acceptable salts thereof, cyclic isomers thereof, prodrugs thereof, and solvates thereof, where all the variables are defined herein. These compounds can be used, alone or in combination with other drugs, for the treatment of diabetes and related diseases.Type: GrantFiled: May 25, 2006Date of Patent: November 2, 2010Inventors: David Alan Campbell, David T. Winn, Juan Manuel Betancort
-
Patent number: 7786312Abstract: In the context of synthesizing heterocyclic boronic acid compounds, a convergent synthetic methodology is particularly efficient for preparing boropyrrolidines and derivatives of boropyrrolidines.Type: GrantFiled: July 27, 2006Date of Patent: August 31, 2010Assignee: Phenomix CorporationInventors: David Alan Campbell, David T. Winn
-
Patent number: 7786163Abstract: Certain constrained cyano compounds are useful as inhibitors of post-proline/alanine cleaving amino-dipeptidases. Accordingly, these compounds can be employed, alone or with another therapeutic agent, to treat diabetes (especially, Type II diabetes), hyperglycemia, Syndrome X, diabetic complications, hyperinsulinemia, obesity, atherosclerosis and related diseases, as well as various immunomodulatory diseases and chronic inflammatory bowel disease.Type: GrantFiled: July 12, 2005Date of Patent: August 31, 2010Inventors: David Alan Campbell, Juan Manuel Betancort, David T. Winn
-
Patent number: 7767828Abstract: The present invention is directed to pyrrolidinylaminoacetyl pyrrolidine boronic acid compounds that display selective, potent dipeptidyl peptidase IV inhibitory activity. These compounds are useful for the treatment of disorders that can be regulated or normalized via inhibition of DPP-IV including those characterized by impaired glycemic control such as Diabetes Mellitus and related conditions. The compounds can be administered alone or with another medicament that displays pharmacological activity for treatment of these and other diseases.Type: GrantFiled: May 1, 2006Date of Patent: August 3, 2010Assignee: Phenomix CorporationInventors: David Alan Campbell, David T. Winn, Juan Manuel Betancort
-
Publication number: 20100120716Abstract: Macrocyclic inhibitors of Hepatitis C protease are provided, the inhibitors including a boronic acid or ester group, a macrocyclic ring of about 13 to 25 atoms including at least two amide linkages, a proline-analogous group, and a connecting segment joining moieties on either side of the proline-analogous group. Methods of making the HCV protease-inhibitory compounds, methods of using the compounds, formulations of the compounds, and pharmaceutical combinations including the compounds, are provided.Type: ApplicationFiled: December 5, 2007Publication date: May 13, 2010Applicant: Phenomix CorporationInventors: David A. Campbell, Michael E. Hepperle, David T. Winn, Juan M. Betancort
-
Publication number: 20100120661Abstract: Dipeptidyl peptidase IV (DPP-IV)-inhibiting compounds are provided that have formula I: wherein n is 1 to 3; X is CH2; S; O; CF2 or C(CH2)2; Z is H; halogen; hydroxyl; (C1-6)alkoxy; (C1-12)alkyl; (C3-12)cycloalkyl; phenyl; or heteroaryl; where the phenyl and heteroaryl groups are optionally mono- or independently plurisubstituted with R7; optionally, X together with an adjacent ring carbon and Z form a fused cyclopropyl; and optionally, one of the bonds in the ring containing X is a double bond; and CriRii, R1, R1, R3, R4 and R5 are as described herein. Methods for preparing these compounds, and methods for treating diabetes, especially Type II diabetes, and other related diseases are described using the compounds of formula I in pharmaceutical compositions which contain these compounds. Pharmaceutical compositions which contain combinations of these compounds with other antidiabetic agents are also described herein.Type: ApplicationFiled: January 22, 2010Publication date: May 13, 2010Applicant: Phenomix CorporationInventors: David A. Campbell, David T. Winn, Juan M. Betancort
-
Patent number: 7674913Abstract: Dipeptidyl peptidase IV (DPP-IV)-inhibiting compounds are provided that have formula I: wherein n is 1 to 3; X is CH2; S; O; CF2 or C(CH3)2; Z is H; halogen; hydroxyl; (C1-6)alkoxy; (C1-12)alkyl; (C3-12)cycloalkyl; phenyl; or heteroaryl; where the phenyl and heteroaryl groups are optionally mono- or independently plurisubstituted with R7; optionally, X together with an adjacent ring carbon and Z form a fused cyclopropyl; and optionally, one of the bonds in the ring containing X is a double bond; and CriRii, R1, R1, R3, R4 and R5 are as described herein. Methods for preparing these compounds, and methods for treating diabetes, especially Type II diabetes, and other related diseases are described using the compounds of formula I in pharmaceutical compositions which contain these compounds. Pharmaceutical compositions which contain combinations of these compounds with other antidiabetic agents are also described herein.Type: GrantFiled: November 12, 2004Date of Patent: March 9, 2010Assignee: Phenomix CorporationInventors: David A. Campbell, David T. Winn, Juan M. Betancort
-
Publication number: 20090325889Abstract: The present invention provides novel compounds which mimic peptides with a C-terminal penultimate proline, such compounds being useful as protease inhibitors, particularly as inhibitors of serine proteases, and more particularly as inhibitors of the NS3 serine protease from hepatitis C. The compounds find utility as antiviral agents directed at hepatitis C. The invention further provides methods of employing such inhibitors, alone or in combination with other therapeutic agents, to treat hepatitis C infection in a subject in need of such treatment.Type: ApplicationFiled: July 28, 2006Publication date: December 31, 2009Inventors: David Alan Campbell, David T. Winn, Juan Manuel Betancort, Michael E. Hepperle
-
Publication number: 20090304631Abstract: The invention provides compounds that inhibit a viral protease enzyme of the hepatitis C virus (HCV). The compounds are adapted for treatment of a HCV infection in a patient with the disease. The compounds include analogs of tripeptides and tetrapeptides that resemble the viral protease substrate. The invention also provides pharmaceutical compositions and combinations, methods of preparation of the compounds, and methods of treatment of patients afflicted with HCV using the compounds.Type: ApplicationFiled: January 25, 2007Publication date: December 10, 2009Inventors: David Alan Campbell, Michael E. Hepperle, Juan Manuel Betancort, David T. Winn
-
Patent number: 7576121Abstract: The present invention is directed to pyrrolidinylaminoacetyl pyrrolidine boronic acid compounds that display selective, potent dipeptidyl peptidase IV (DPP-IV) inhibitory activity. These compounds are useful for the treatment of disorders that can be regulated or normalized via inhibition of DPP-IV including those characterized by impaired glycemic control such as Diabetes Mellitus and related conditions. The compounds can be administered alone or with another medicament that displays pharmacological activity for treatment of these and other diseases.Type: GrantFiled: May 1, 2006Date of Patent: August 18, 2009Assignee: Phenomix CorporationInventors: David Alan Campbell, David T. Winn, Juan Manuel Betancort
-
Publication number: 20080300413Abstract: In the context of synthesizing heterocyclic boronic acid compounds, a convergent synthetic methodology is particularly efficient for preparing boropyrrolidines and derivatives of boropyrrolidines.Type: ApplicationFiled: July 27, 2006Publication date: December 4, 2008Inventors: David Alan Campbell, David T. Winn
-
Publication number: 20080182995Abstract: The present invention is directed to pyrrolidinylaminoacetyl pyrrolidine boronic acid compounds that display selective, potent dipeptidyl peptidase IV inhibitory activity. These compounds are useful for the treatment of disorders that can be regulated or normalized via inhibition of DPP-IV including those characterized by impaired glycemic control such as Diabetes Mellitus and related conditions. The compounds can be administered alone or with another medicament that displays pharmacological activity for treatment of these and other diseases.Type: ApplicationFiled: October 31, 2007Publication date: July 31, 2008Inventors: David A. Campbell, David T. Winn, Juan Manuel Betancort
-
Patent number: 7317109Abstract: The present invention is directed to pyrrolidinylaminoacetyl pyrrolidine boronic acid compounds that display selective, potent dipeptidyl peptidase IV inhibitory activity. These compounds are useful for the treatment of disorders that can be regulated or normalized via inhibition of DPP-IV including those characterized by impaired glycemic control such as Diabetes Mellitus and related conditions. The compounds can be administered alone or with another medicament that displays pharmacological activity for treatment of these and other diseases.Type: GrantFiled: May 1, 2006Date of Patent: January 8, 2008Assignee: Phenomix CorporationInventors: David Alan Campbell, David T. Winn, Juan Manuel Betancort
-
Publication number: 20040186132Abstract: Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.Type: ApplicationFiled: December 17, 2003Publication date: September 23, 2004Inventors: Todd K. Jones, Mark E. Goldman, Charlotte L. F. Pooley, David T. Winn, James P. Edwards, Sarah J. West, Christopher M. Tegley, Lin Zhi, Lawrence G. Hamann, Luc J. Farmer, Robert L. Davis
-
Patent number: 6696459Abstract: Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.Type: GrantFiled: October 14, 1997Date of Patent: February 24, 2004Assignee: Ligand Pharmaceuticals Inc.Inventors: Todd K. Jones, Mark E. Goldman, Charlotte L. F. Pooley, David T. Winn, James P. Edwards, Sarah J. West, Christopher M. Tegley, Lin Zhi, Lawrence G. Hamann, Luc J. Farmer, Robert L. Davis
-
Patent number: 6121450Abstract: Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.Type: GrantFiled: October 8, 1997Date of Patent: September 19, 2000Assignee: Ligand Pharmaceuticals IncorporatedInventors: Todd K. Jones, David T. Winn, Lawrence G. Hamann, Lin Zhi, Luc J. Farmer, Robert L. Davis